Phase I study of oral gemcitabine prodrug

Apr 13, 2017 - Keywords: gemcitabine, LY2334737, erlotinib, oral administration ...... disposition of gemcitabine, and oncolytic deoxycytidine analog,...

1 downloads 0 Views 433KB Size

Recommend Documents

Among them are polar-planar compounds, such as N-methyl formamide and hexamethylene bisacetamide. ( 1. ). low doses of cytotoxic drugs. (1), phenylacetate.

Apr 6, 2015 - The extent of residual disease was assessed using the ..... Urinary tract infection. 1 ..... Medical Center, Dallas, TX; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; ... Consulting or Advisory Role: Oncoplex DX, Vertex.

ANTICANCER RESEARCH 30: 3817-3822 (2010). 3820. Table V. Toxicity. Toxicity. Grade 1 .... C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Postlberger.

indicate this fact. Requests for reprints: Thierry Le Chevalier, Department of Medicine, ..... In most multicenter trials of double chemo- therapy combinations in ...

Apr 10, 2017 - IgG-negative control signals (assay background) were assigned a value of 1, and ... PCR fragments were then analyzed by Surveyor Nuclease.

May 18, 1995 - African medicinal plants: 11. Hypoxoside ... Van der Merwe MJ, Jenkins K. Theron E, Van der Wait SJ. ... The quantitative sequestration of rooperol metabolites in ... by the chemical pathology and haematology laboratories at.

comfort and cramping, was the principal dose-limiting tox- icity of S-1 on this .... of 1,000/l associated with fever (38.5°C); (f) omission of. 25% of the planned dose ...

frequently identified resistance mechanism to EGFR tyro- sine kinase inhibitors ... were administered once daily to non–small cell lung cancer. (NSCLC) patients ..... than the response rate seen in the phase I study of osimertinib, the currently ..

3 weeks (15 doses/course) followed by 2– 4 weeks of rest. The. DLTs occurring ... patients with RAEB, RAEB in transformation, and CMML (9). ..... Twenty-one febrile episodes ...... Miller, K. B., Kim, K., Morrison, F. S., Winter, J. N., Bennett, J.

9-AC,3 9-nitrocamptothecin, topotecan, irinotecan, karenitecin, and DX-8951f ... of 12 weeks, adequate bone marrow reserve (defined as ab- solute neutrophil ...

Apr 15, 2017 - antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide ..... Rigosertib has a side-effect pattern different from other.

Stephen P. Letrent,2 Bharat Damle,2. Arthur P. DeCillis,2 and Eric K. Rowinsky1. 1Institute for ... which fewer than two of the first six new patients experi- enced dose-limiting toxicity. The pharmacokinetic profiles .... a once-daily schedule to im

Mar 15, 2010 - Note: This article is part of a two-part study of PD-0325901. ...... C, Kaplan-Meier analysis of PFS in patients with pERK decrease ≥60% versus .... committee for the NCI; sat on a data safety monitoring committee for Syn- dax.

tumors. Clin Cancer Res; 1–8. Ó2014 AACR. Introduction. The Hedgehog (Hh) signaling pathway is a key regulator of cell growth, self-renewal, patterning, and differentiation during ... cancer, and soft tissue- or cartilage-derived sarcoma) that wer

them, to break down all of the components of the ECM, includ- ing the basement membrane (1). ... novel synthetic hydroxamic acid derivative (Fig. 1) able to .... (free base). 1913 ..... We wish to thank Drs. T. S. Ganesan and N. Dobbs (Imperial.

the possibility of circadian. FU kinetics contributing to the results. A 28-day schedule ... II studies, although toxicity requiring cessation of drug administration prior ..... have been documented to benefit from fluoropyrimidines, even after faili

Feb 26, 2015 - OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor ... Patients received OPB-31121 once daily for 28 days of each cycle ...

Jan 21, 2013 - Chang, Michael Shi, and Andrea Kay are employees of Novartis ...... Grünwald V, Ravaud A, Castellano DE, Lin C, Gschwend JE, et al. A.

Oct 13, 2009 - Experimental Design: Cancer patients (n = 81) received oral doses of lapatinib ranging ... tute, 250 25th Avenue North, Suite 110, Nashville, TN 37203. ..... intestinal obstruction (8%), nausea (6%), vomiting (6%), and dehy-.

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...

Mar 28, 2008 - .4000/mm3 and ,12 000/mm3, neutrophil count .2000/ mm3 and platelet ..... cancertopics/pdq/treatment/pancreatic/healthprofessional/. 2. Burris.

Anderson cancer center, 1515 Holcombe Blvd. Houston, TX 77030. Phone: 713-792-2817; Fax: ... Received: 2013.12.06; Accepted: 2014.02.01; Published: 2014.03.29. Abstract ... days 1 and 8 in combination with 15 mg/m2 of V on days 2 and 9, every 21 days

Oct 30, 2009 - vincristine and cyclophosphamide (ADOC) reported an overall RR of 92% and .... ctcaev3.pdf (1 May 2009, date last accessed). 13. Kaplan EL ...

Jan 22, 2012 - Clinical Study. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic. Squamous Cell Carcinoma of the Head and ... 2 Division of Hematology/Oncology, St. John Hospital, Wayn